CXCL8 and rheumatoid arthritis: Clinical trials using CXCL8 or CXCR1/2 inhibitors in treatment of other inflammatory diseases (including COPD, rheumatoid arthritis, asthma, psoriasis, palmoplantar pustulosis), type I diabetes, or to prevent transplant rejection have shown that neutralizing antibodies or small molecule antagonists are inherently safe for use in patients, with no significant adverse events detected relative to placebo-treated groups.